Ingevity Corporation
NYSE:NGVTChemicals - Specialty
+$0.81 today
- Market cap
- $1.97B
- Beta
- 1.19
- P/E (TTM)
- -20.0
- EPS (TTM)
- -$3.62
Volume 0.37M
Average 0.26M
NGVT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Ingevity CorporationNYSE: NGVT
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables outflow shrinks to $0
Q3 FY2026 accounts receivables was $0, compared with $15.2M a year earlier. Trailing-twelve-month accounts receivables was $5.1M.
Context
- Accounts receivables amounted to 1.0% of revenue in FY2025, down 1.7 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.28M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 12.2M USD
- Year-over-year change
- -68.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.2M | -68.1% |
| FY2024 | 2024-12-31 | 38.2M | -10.5% |
| FY2023 | 2023-12-31 | 42.7M | +201.4% |
| FY2022 | 2022-12-31 | (42.1M) | -205.1% |
| FY2021 | 2021-12-31 | (13.8M) | — |
Accounts Receivables vs competitors
How NGVT compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -54.9% is the 6th highest of 9, against a peer median of +87.6%.
- Accounts receivables amounts to 0.5% of revenue for NGVT, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $129.2M USD | +169.6% | — | 3.8% | |
AAUCAllied Gold Corporation | LTM Jun 2026 | $97.36M USD | +58.0% | +56.7% | 6.5% |
| LTM Jun 2026 | $91.2M USD | +328.2% | — | 5.0% | |
| LTM Jun 2026 | $83.9M USD | +172.3% | -8.4% | 1.3% | |
| LTM Sep 2026 | $53.27M USD | -696.2% | — | 2.6% | |
ELVRElevra Lithium Limited | FY2025 | A$32.31M AUD | — | — | 15.6% |
| LTM Jun 2026 | $15M USD | -61.5% | +5.2% | 0.3% | |
| LTM Sep 2026 | $5.1M USD | -54.9% | — | 0.5% | |
| LTM Sep 2026 | CA$1.25M CAD | +117.2% | — | — | |
| LTM Jun 2026 | $0 USD | -100.0% | — | 0.0% | |
| LTM Apr 2026 | $0 USD | — | -52.4% | 0.0% | |
| Peer median (excluding NGVT) | — | +87.6% | -1.6% | 2.6% | |
Competitors are the stored peer set for NGVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 118.1M | 211.6M | (5.4M) | (430.3M) | (167.1M) |
| Depreciation & Amortization | 109.9M | 108.8M | 122.8M | 108.3M | 106.4M |
| Deferred Income Tax | (4.6M) | (5M) | (44.7M) | (121.4M) | (4.7M) |
| Stock-Based Compensation | 12.3M | 16.1M | 10.6M | 11.9M | 18.3M |
| Change in Working Capital | 30.5M | (66.5M) | (67.8M) | (10M) | 22.7M |
| Accounts Receivables | (13.8M) | (42.1M) | 42.7M | 38.2M | 12.2M |
| Inventory | (55.8M) | (63.7M) | 25.8M | 86.2M | 40.2M |
| Accounts Payables | 14.8M | 42.7M | (14.6M) | (63.4M) | (2.6M) |
| Other Working Capital | 85.3M | (3.4M) | (121.7M) | (71M) | (27.1M) |
| Other Non-Cash Items | 27.1M | 48.4M | 189.6M | 570.1M | 355.6M |
| Operating Cash Flow | 293.3M | 313.4M | 205.1M | 128.6M | 331.2M |
| Capital Expenditures | (103.8M) | (142.5M) | (109.8M) | (77.6M) | (57.7M) |
| Acquisitions (Net) | 0 | (344.5M) | 0 | 0 | 0 |
| Purchases of Investments | (35.3M) | (77.4M) | (2.4M) | (300K) | (16.4M) |
| Sales of Investments | 0 | 14.7M | 31.5M | 0 | 13M |
| Other Investing Activities | 500K | (2.2M) | 3.4M | (1.6M) | 3.6M |
| Investing Cash Flow | (138.6M) | (551.9M) | (77.3M) | (79.5M) | (57.5M) |
| Debt Repayment | (26M) | 199M | (6.6M) | (67.1M) | (193.6M) |
| Common Stock Issued | 4.7M | 0 | 4.7M | 0 | 1.4M |
| Common Stock Repurchased | (109.4M) | (145.2M) | (92.1M) | (3.1M) | (56.3M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.4M) | (5.7M) | (5.9M) | 0 | (3.7M) |
| Financing Cash Flow | (133.1M) | 48.1M | (99.9M) | (70.2M) | (252.2M) |
| Effect of Forex Changes | (1.7M) | (6M) | (300K) | (4.2M) | 4.5M |
| Net Change in Cash | 19.9M | (196.4M) | 27.6M | (25.3M) | 26M |
| Free Cash Flow | 189.5M | 170.9M | 95.3M | 51M | 273.5M |
Ingevity Corporation
NYSE:NGVT
Intrinsic Alpha fair value
Locked
Current Price
$58.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.